ArticleJournal of ophthalmology2026
Impact of Comorbid Hypertension and Diabetes on Anti-VEGF Treatment Outcomes in Macular Edema.
Article in Journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of Comorbid Hypertension and Diabetes on Anti-VEGF Treatment Outcomes in Macular Edema.Journal of ophthalmology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study evaluated the effects of intravitreal injection of antivascular endothelial growth factor (VEGF) treatment on visual acuity and macular edema severity in patients with comorbid hypertension and diabetes macular edema in China. Method: A longitudinal observational study, involving a total of 89 cases with macular edema who received anti-VEGF injection treatment, compared the changes in visual acuity and macular edema severity among four groups of patients at three different time points. Additionally, through regression analysis, it explored the changes in best-corrected visual acuity (BCVA) and central macular thickness (CMT) in patients with hypertension and diabetes after receiving different numbers of anti-VEGF treatments, as well as the relationship between the number of injections and visual improvement and edema reduction. Results: Significant improvements in BCVA and CMT were observed following anti-VEGF treatment, most notably after the first injection. The group without comorbidities demonstrated the greatest improvements, with BCVA improving from 0.20 to 0.40 logMAR and CMT decreasing from approximately 600 μm to 200 μm. In contrast, patients with hypertension and/or diabetes exhibited attenuated therapeutic responses. Multifactorial regression analysis confirmed that the presence of hypertension and/or diabetes served as an independent negative predictor for both BCVA improvement ( Conclusion: In summary, patients with both hypertension and diabetes face greater challenges in terms of their overall health condition, the rate of vision decline, and the improvement of macular edema. It is recommended to initiate treatment for patients with comorbidities earlier, increase the number of injections, and combine other therapies to enhance the treatment effect. Trial Registration: Taizhou Municipal Hospital: LWYJ2025268.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.